健麾信息(605186.SH)公告称，公司拟以3768.75万元、2285.63万元、637.50万元、679.14万元分别收购 周校平、泽朴投资、博科医信、博科国信持有的博科国信（武汉）科技有限公司16.75%、13.25%、 4.00%、4.00%股权。交易完成后，健麾信息将持有标的公司70%的股权。标的公司是中国医疗卫生信息 互联互通技术联盟暨HL7 China的会员单位，是中部地区首家通过FHIR Connectathon 13项系统测试的医 疗信息化企业。标的公司在医疗AI应用（如B-Klinik智能体）方面的研发积累，将为公司核心业务注入 智能化创新动能，有助于开拓在智慧医院、县域医共体及数智康养等领域的业务机会。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

每经AI快讯，健麾信息2月5日晚间发布公告称，公司第三届第十二次董事会会议于2026年2月5日以现 场结合通讯方式召开。会议审议了《关于部分募投项目延期的议案》等文件。 每经头条（nbdtoutiao）——仅老年独居者就数千万，谁能帮他们从容老去？意定监护在国内诞生已14 年，距全面落地还差"最后一公里" （记者 曾健辉） ...

Core Viewpoint - The company, Jianhui Information, is acquiring additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, which will make Boke Guoxin a subsidiary and included in the consolidated financial statements [1] Group 1: Transaction Details - The company plans to acquire 16.75%, 13.25%, 4.00%, and 4.00% equity stakes from Zhou Xiaoping, Ze Pu Investment, Boke Yixin, and Boke Guoxin for a total of RMB 37.6875 million, 22.8563 million, 6.375 million, and 6.7914 million respectively [1] - After the transaction, Zhou Xiaoping will hold the remaining 30% of Boke Guoxin [1] Group 2: Strategic Importance - This transaction is a key measure for the company to implement its intelligent development strategy and deepen industry chain collaboration [1] - Increasing the stake in Boke Guoxin will facilitate the integration of both parties' technological advantages in automation hardware, software platforms, and medical AI [1] Group 3: Market Expansion and Innovation - Boke Guoxin is a member of the China Healthcare Information Interconnection Technology Alliance and has extensive development experience with the HL7 international medical information standards, which will aid the company's overseas market expansion [2] - The acquisition will accelerate the company's business development in emerging markets such as county-level medical communities and data governance for medical institutions [2] - The integration of business and resource sharing is expected to enhance the company's technological innovation capabilities and market responsiveness, laying a solid foundation for future performance growth [2]

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

每经AI快讯，2月5日，健麾信息（605186）(605186.SH)公告称，公司拟以3768.75万元、2285.63万元、 637.50万元、679.14万元分别收购周校平、泽朴投资、博科医信、博科国信持有的博科国信(武汉)科技 有限公司16.75%、13.25%、4.00%、4.00%股权。交易完成后，健麾信息将持有标的公司70%的股权。 标的公司是中国医疗卫生信息互联互通技术联盟暨HL7China的会员单位，是中部地区首家通过FHIR Connectathon13项系统测试的医疗信息化企业。标的公司在医疗AI应用(如B-Klinik智能体)方面的研发积 累，将为公司核心业务注入智能化创新动能，有助于开拓在智慧医院、县域医共体及数智康养等领域的 业务机会。 ...

智通财经APP讯，健麾信息(605186.SH)发布公告，公司拟以3,768.75万元、2,285.63万元、637.50万元、 679.14万元分别收购周校平、泽朴投资、博科医信、博科国信持有的博科国信(武汉)科技有限公司(简 称"标的公司")16.75%、13.25%、4.00%、4.00%股权。本次交易前，健麾信息持有标的公司32%的股权; 本次交易完成后，健麾信息将持有标的公司70%的股权，周校平持有标的公司剩余30%的股权，标的公 司将成为公司的控股子公司并纳入合并报表。 本次交易还将有助于加速公司在县域医共体、医疗机构数据治理等新兴市场的业务拓展，能够推动公司 深度打造"软硬件一体化+AI"的智慧医疗综合服务。通过业务整合与资源共享，有利于提升公司的技术 创新能力和市场响应速度，为未来业绩增长奠定坚实基础。 本次交易是公司落实智能化发展战略、深化产业链协同的关键举措。通过进一步提升对标的公司的持股 比例并实现控股，有利于公司全面整合双方在自动化硬件、软件平台及医疗人工智能领域的技术优势。 这将有效推动公司现有自动化药房、静配中心等核心设备产品与标的公司在B-Klinik智能体、智慧运营 管理平台、 ...

Core Viewpoint - The company, Jianhui Information, plans to acquire additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, thereby making it a subsidiary and consolidating its financials [1][2] Group 1: Acquisition Details - The company intends to purchase 16.75%, 13.25%, 4.00%, and 4.00% equity stakes from Zhou Xiaoping, Ze Pu Investment, Boke Yixin, and Boke Guoxin for a total of RMB 37.6875 million, 22.8563 million, 6.375 million, and 6.7914 million respectively [1] - Post-transaction, Zhou Xiaoping will retain the remaining 30% equity in the target company [1] Group 2: Strategic Importance - This acquisition is a key move for the company to implement its intelligent development strategy and deepen industry chain collaboration [1] - By increasing its stake, the company aims to integrate its automation hardware, software platforms, and medical AI capabilities with those of the target company [1] Group 3: Market Expansion and Innovation - The target company is a member of the China Healthcare Information Interconnection Technology Alliance and has extensive experience with the HL7 international medical information standards, which will facilitate the company's expansion into overseas markets [2] - The transaction is expected to accelerate the company's business development in emerging markets such as county-level medical communities and data governance for medical institutions [2] - Through business integration and resource sharing, the company aims to enhance its technological innovation capabilities and market responsiveness, laying a solid foundation for future performance growth [2]

国信证券股份有限公司 关于上海健麾信息技术股份有限公司 部分募投项目延期的核查意见 国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为上海 健麾信息技术股份有限公司（以下简称"健麾信息"或"公司"）首次公开发行 股票并在主板上市（以下简称"本次发行"）的保荐机构，根据《证券发行上市 保荐业务管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》《上市公司募集资金监管规则》《上海证券交易所股票上市规则》和《上海 证券交易所上市公司自律监管指引第 11 号——持续督导》等有关规定，就健麾 信息部分募集资金投资项目延期事项进行了审慎核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于核 准上海健麾信息技术股份有限公司首次公开发行股票的批复》（证监许可 [2020]3211 号），公司于 2020 年 12 月首次公开发行人民币普通股（A 股） 34,000,000 股。公司每股发行价格为人民币 14.20 元，本次募集资金总额为人民 币 482,800,000.00 元，扣除各项发行费用（不含增值税）人民币 47,588,127. ...

证券代码：605186 证券简称：健麾信息 公告编号：2026-003 上海健麾信息技术股份有限公司 关于收购子公司博科国信（武汉）科技有限公司 部分股权的公告 本次收购是公司从长期发展战略布局出发的慎重决定，虽然进行了充分 的必要性和可行性论证分析，但仍然可能面临市场、经营管理等各方面不确 定因素带来的风险，以及资源整合未达预期效果的风险。本次交易中，交易 各方尚未签署《股权转让协议》，后续尚需办理工商变更登记程序，能否实 施完成尚存在不确定性，本次收购存在一定的投资风险，详见本公告第七部 分。敬请投资者理性判断，注意投资风险。 一、交易概述 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容 上海健麾信息技术股份有限公司（以下简称"公司"或"健麾信息"） 拟以人民币 3,768.75 万元、2,285.63 万元、637.50 万元、679.14 万元分 别收购周校平、武汉泽朴投资有限公司（以下简称"泽朴投资"）、武汉博 科医信信息技术合伙企业（有限合伙）（以下简称"博科医信"）、武汉博 科国信信 ...

重要内容提示： 证券代码：605186 证券简称： 健麾信息 公告编号：2026-002 上海健麾信息技术股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海健麾信息技术股份有限公司（以下简称"公司"）于 2026 年 2 月 5 日 召开第三届董事会第十二次会议，审议通过了《关于部分募投项目延期的议案》。 在募投项目实施主体、募集资金投资用途及投资规模不发生变更的情况下，公司 根据目前募投项目的实施进度，拟将部分募投项目延期至 2027 年 2 月。本事项 在董事会审议权限范围内，无需提交股东会审议。具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 三、募集资金投资项目延期的情况说明 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于核 准上海健麾信息技术股份有限公司首次公开发行股票的批复》（证监许可 [2020]3211号），公司于2020年12月首次公开发行人民币普通股（A股）34,000,000 股。公司每股发行价格为人民币 14.20 ...